IRadimed Corporation (IRMD) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

IRadimed Corporation (IRMD) Healthcare & Pipeline Overview

IRadimed Corporation is a leader in the MRI-compatible medical device market, offering specialized infusion pumps and patient monitoring systems. With a strong emphasis on safety and compatibility, IRadimed serves hospitals and outpatient imaging centers, distinguishing itself through direct sales and clinical support.

What Is the Investment Thesis for IRMD?

IRadimed Corporation presents a compelling investment case due to its specialized niche in MRI-compatible medical devices. With a market capitalization of $1.12B and a P/E ratio of 49.7, the company demonstrates strong profitability, supported by a profit margin of 27.4% and a gross margin of 76.8%. A dividend yield of 1.40% provides additional investor return. Ongoing catalysts include continued adoption of MRI-compatible devices in hospitals and imaging centers, driven by increasing MRI procedure volumes. Potential risks include competition from larger medical device companies and regulatory changes affecting medical device approvals. The company's beta of 1.12 suggests moderate volatility relative to the market.

Based on FMP financials and quantitative analysis

IRMD Key Highlights

Market capitalization of $1.12B reflects investor confidence in IRadimed's market position.

• P/E ratio of 49.7 indicates a premium valuation, potentially reflecting growth expectations.
• Profit margin of 27.4% showcases strong operational efficiency and profitability.
• Gross margin of 76.8% highlights the value-added nature of IRadimed's specialized products.
• Dividend yield of 1.40% provides a steady income stream for investors.

Who Are IRMD's Competitors?

IRMD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are IRMD's Key Strengths?

Specialized expertise in MRI-compatible medical devices

• Strong gross and profit margins
• Established customer base in hospitals and imaging centers
• Proprietary technology and regulatory approvals

What Are IRMD's Weaknesses?

Limited product portfolio compared to larger medical device companies

• Reliance on a niche market
• Potential vulnerability to technological obsolescence
• Smaller scale limits negotiating power with suppliers

What Could Drive IRMD Stock Higher?

Increasing adoption of MRI-compatible devices in hospitals and imaging centers.

• Growing demand for MRI procedures due to advancements in diagnostic imaging.
• Potential regulatory approvals for new MRI-compatible devices.
• Expansion into new international markets.

What Are the Key Risks for IRMD?

Rich valuation — a P/E of 49.7 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.

• Insider selling — insiders were net sellers of roughly $3.3M recently.
• Competition from larger medical device companies with greater resources.
• Regulatory changes affecting medical device approvals and reimbursement.
• Technological advancements rendering existing products obsolete.
• Economic downturn impacting healthcare spending and capital equipment purchases.

What Are the Growth Opportunities for IRMD?

• Expansion into International Markets: IRadimed has the opportunity to expand its presence in international markets, particularly in regions with growing healthcare infrastructure and increasing adoption of MRI technology. This expansion can be achieved through strategic partnerships with local distributors and targeted marketing efforts. The global MRI market is projected to reach $7 billion by 2028, providing a substantial opportunity for IRadimed to increase its international sales.
• Development of New MRI-Compatible Devices: IRadimed can drive growth by investing in the development of new MRI-compatible medical devices. This includes exploring opportunities in areas such as MRI-compatible pacemakers, defibrillators, and other implantable devices. The market for MRI-compatible implantable devices is expected to grow significantly as the population ages and the demand for these devices increases.
• Enhancement of Existing Product Portfolio: IRadimed can enhance its existing product portfolio by adding new features and functionalities to its MRidium MRI compatible IV infusion pump system and patient vital signs monitoring system. This includes incorporating advanced monitoring capabilities, improving user interfaces, and enhancing data connectivity. These enhancements can increase the value proposition of IRadimed's products and attract new customers.
• Strategic Acquisitions: IRadimed can pursue strategic acquisitions of companies with complementary technologies or product lines. This can help IRadimed expand its product offerings, enter new markets, and gain access to new customers. Potential acquisition targets include companies specializing in MRI coil technology, contrast agents, or image processing software.
• Focus on Outpatient Imaging Centers: IRadimed can focus on expanding its sales to outpatient imaging centers, which are experiencing rapid growth due to their convenience and cost-effectiveness. This can be achieved through targeted marketing efforts and the development of products specifically tailored to the needs of outpatient imaging centers. The outpatient imaging center market is expected to continue to grow as healthcare providers seek to reduce costs and improve patient access to care.

What Are IRMD's Competitive Advantages?

• Specialized Expertise: Deep understanding of MRI compatibility requirements.
• Proprietary Technology: Patented technologies for MRI-safe medical devices.
• Regulatory Approvals: FDA clearances and other regulatory approvals create barriers to entry.
• Established Customer Relationships: Long-standing relationships with hospitals and imaging centers.

What Does IRMD Do?

IRADIMED CORPORATION, founded in 1992 and headquartered in Winter Springs, Florida, is a global leader in the development, manufacture, marketing, and distribution of magnetic resonance imaging (MRI) compatible medical devices, accessories, and related services. The company's core product offerings include the MRidium MRI compatible intravenous (IV) infusion pump system, which is designed to safely deliver medication and fluids to patients during MRI procedures. This system is complemented by associated disposable IV tubing sets, ensuring a complete solution for medical professionals. Additionally, IRADIMED offers an MRI compatible patient vital signs monitoring system, which allows for continuous monitoring of critical patient parameters within the MRI environment. Beyond these primary systems, IRADIMED provides a range of accessories, including non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring solutions with sensors. These accessories enhance the functionality and usability of their core products. IRADIMED serves a diverse customer base, including hospitals, acute care facilities, and outpatient imaging centers, both in the United States and internationally. The company employs a direct sales force, regional sales directors, clinical support representatives, and independent distributors to reach its customers and provide comprehensive support.

What Products and Services Does IRMD Offer?

• Develops MRI-compatible intravenous (IV) infusion pump systems.
• Manufactures MRI-compatible patient vital signs monitoring systems.
• Markets and distributes MRI-compatible medical devices.
• Offers related accessories such as non-magnetic IV poles and wireless remote controls.
• Provides services related to MRI-compatible medical devices.
• Sells products through direct field sales representatives and distributors.
• Offers dose error reduction systems and SpO2 monitoring solutions.

How Does IRMD Make Money?

• Develops and manufactures specialized MRI-compatible medical devices.
• Sells these devices and related accessories to hospitals and outpatient imaging centers.
• Provides ongoing service and support for its products.
• Generates revenue through direct sales and distribution partnerships.

What Industry Does IRMD Operate In?

IRadimed Corporation operates within the medical device industry, specifically focusing on MRI-compatible devices. The global medical device market is experiencing steady growth, driven by technological advancements, an aging population, and increasing healthcare expenditure. The demand for MRI-compatible devices is rising as MRI procedures become more prevalent. IRadimed's competitive landscape includes both specialized players and larger medical device companies that offer MRI-compatible products. The company differentiates itself through its exclusive focus on MRI compatibility and its comprehensive product portfolio.

Who Are IRMD's Key Customers?

• Hospitals
• Acute care facilities
• Outpatient imaging centers

Company Profile

IRadimed Corporation operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Orlando, US. The company is led by CEO Roger E. Susi. IRMD has traded publicly since 2014.

IRadimed Corporation Financial Trajectory

IRadimed Corporation (IRMD) reported $20.5M in revenue for Q2 2026, a decline of 6.9% compared to the prior quarter. The company recorded net income of $5.2M, with diluted EPS of $0.41. Revenue has contracted over three consecutive quarters, which investors in this small-cap Healthcare stock should monitor closely. Across the four most recent quarters, IRMD averaged $0.45 in diluted EPS.

How IRadimed Corporation Is Valued

IRadimed Corporation carries a market capitalization of $1.12B, placing it in the small-cap category. Relative to its peer group, IRMD's quantitative score of 94/100 is above the peer average of 70/100.

Return on equity for IRadimed Corporation stands at 24.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 20.6%, showing how much profit it generates from its asset base. IRMD trades at a trailing price-to-earnings ratio of 49.72, above the Healthcare sector average of ~23x. Its free cash flow yield is 2.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 7.13 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.0%, the inverse of the P/E and a quick read on earnings relative to price.

IRadimed Corporation's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 53.93 places it in the safe zone, indicating low near-term bankruptcy risk.

IRadimed Corporation has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 4.5% above estimates on average.

Wall Street analysts project IRadimed Corporation revenue of about $91.2M for fiscal 2026, with EPS near $2.09.

Over the past six months, IRadimed Corporation insiders filed 30 SEC Form 4 transactions — 29 sales and 1 purchases. On net that is roughly 38K shares disposed (about $3.3M), a signal worth weighing alongside the fundamentals.

IRMD Financials

IRMD Latest News

IRMD Analyst Consensus

IRMD MoonshotScore

Common Questions About IRMD (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources